762 reports of this reaction
2.1% of all RIFAXIMIN reports
#9 most reported adverse reaction
HEPATIC ENCEPHALOPATHY is the #9 most commonly reported adverse reaction for RIFAXIMIN, manufactured by Salix Pharmaceuticals, Inc.. There are 762 FDA adverse event reports linking RIFAXIMIN to HEPATIC ENCEPHALOPATHY. This represents approximately 2.1% of all 37,072 adverse event reports for this drug.
Patients taking RIFAXIMIN who experience hepatic encephalopathy should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEPATIC ENCEPHALOPATHY is a less commonly reported adverse event for RIFAXIMIN, but still significant enough to appear in the safety profile.
In addition to hepatic encephalopathy, the following adverse reactions have been reported for RIFAXIMIN:
HEPATIC ENCEPHALOPATHY has been reported as an adverse event in 762 FDA reports for RIFAXIMIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEPATIC ENCEPHALOPATHY accounts for approximately 2.1% of all adverse event reports for RIFAXIMIN, making it a notable side effect.
If you experience hepatic encephalopathy while taking RIFAXIMIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.